Next-generation sequencing, a global market valued at more than $3 billion, has grown exponentially as its DNA-analyzing machines are increasingly leveraged for applications in drug development, diagnostics, personalized medicine, population-scale genetic research and more. By 2024, the market is expected to more than triple in size, according to estimates from Grand View Research.
But despite this robust growth, many potential markets have still not been able to efficiently tap into the benefits of modern sequencing technology, which currently prefers centralized, high-throughput utilization and can be cost-prohibitive (and often, time- and resource-intensive) for smaller labs, emerging markets and new, promising applications. Technologies aiming to de-centralize sequencing have had to compromise on accuracy and have had to spend enormous resources and time, constraining the potential benefits of such accessibility.
The sequencing market today is dominated by a very small number of manufacturers that offer products tailored to high-throughput or high-cost applications; these products offer very little flexibility in terms of performance specifications once the commitment is made to operate within one ecosystem. A lab with more modest needs, especially that change over time, depending on applications, does not have many adaptable options. Nor do labs with small budgets, those working on niche applications or those that operate in remote areas.
The market is in need of new sequencing options that fill current gaps and adjusts to the changing needs of users — particularly, customers focused on lower throughput applications, and for whom a diversity of performance specifications (speed, throughput, cost etc.) could be important. These customers need a flexible and affordable solution that they can modify over time, or on the fly, as they pursue answers to pressing scientific and medical questions. A wealth of opportunities exist for high-accuracy genomics in a de-centralized, massively-accessible context — truly bringing sequencing to the masses. A company that could provide such a solution would be able to empower a massive categorical shift in the way that sequencing is used to understand and improve individual wellbeing, human health and environmental health.